DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Amlodipine 10mg Drug Use Investigation

Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Amlodipine (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Summary

In this survey, to collect the safety and efficacy information in the subjects who have been treated with amlodipine 5mg at least 4 weeks in daily practice.

Clinical Details

Official title: Enhanced Dose Norvasc Treatment For Essential Hypertension In Realworld (Norvasc®10mg Drug Use Investigation)

Study design: Observational Model: Case-Only, Time Perspective: Prospective

Primary outcome:

The frequency of treatment related adverse events.

The achievement rate to Blood Pressure Goal.

Secondary outcome:

Treatment related unlisted adverse events in Japanese Package Insert.

Risk factors likely to affect the frequency of treatment related adverse events.

Risk factors likely to affect the efficacy.

Detailed description: All the subjects whom an investigator prescribes Amlodipine (Norvasc®) 10mg Tablet should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Eligibility

Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or female subjects who have been treated with amlodipine 5mg at least 4 weeks

- The subjects who had not achieved target BP

Exclusion Criteria:

- Subjects who have been prescribed amlodipine (Norvasc®) 10mg Tablet before

Locations and Contacts

Additional Information

To obtain contact information for a study center near you, click here.

Starting date: December 2010
Last updated: January 9, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017